Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated April 2026
If you are a parent watching your 14-year-old son still look like a 12-year-old, or a man who remembers being the last in your grade to hit a growth spurt, you already know the quiet anxiety that delayed puberty creates. It is tempting to accept the standard reassurance: “He is just a late bloomer. Give it time.” For about two-thirds of boys, that advice is correct. For the other third, it is wrong, and the delay in treatment can cost inches of adult height, lifelong bone density, future fertility, and years of psychosocial well-being.
This guide walks through the distinction that pediatric endocrinologists use to separate Constitutional Delay of Growth and Puberty (CDGP) from Congenital Hypogonadotropic Hypogonadism (CHH) and other pathological causes. You will learn the age-specific decision points, the clinical red flags that should end the “watchful waiting” conversation immediately, and the pharmacological options available once a diagnosis is made. The information here is built on current peer-reviewed literature and two decades of community experience at ExcelMale.com, where many members are living with the downstream consequences of a delayed or missed diagnosis.
• How clinicians distinguish benign CDGP from permanent hypogonadism
• The red flags that should trigger urgent evaluation rather than reassurance
• When testosterone is the right first-line therapy, and when gonadotropins are better
• The psychosocial and skeletal costs of treating too late
About 95% of boys hit this milestone between 9.5 and 13.5 years of age. The “age 14 rule” is a statistical cutoff that sits roughly 2 to 2.5 standard deviations beyond the mean. When a boy reaches age 14 without that 4 ml landmark, he meets the formal definition of delayed puberty, and the question is no longer whether to investigate but what the underlying cause is.
There is a second pattern that is just as important and often missed: arrested puberty. If a boy starts puberty on schedule but then stalls, with no change in genital stage or testosterone for more than a year, or fails to complete development (adult testicular volume of 15 ml and Tanner stage 5) within five years of onset, that is also a medical finding. Starting is only half the battle. The tempo of progression must be tracked too.
The three broad categories every clinician considers:
Primary hypogonadism is easy to identify biochemically because the gonadotropins are elevated. The hard case is separating CDGP from CHH, and the tools available are imperfect. Bone age radiographs help: a significantly delayed bone age relative to chronological age leans toward CDGP. Family history of late puberty in a parent or sibling also favors CDGP. A recent comprehensive review notes that serum inhibin B and anti-Müllerian hormone (AMH) may be valuable differentiators, because they reflect Sertoli cell activity and tend to be lower in CHH than in CDGP. However, overlap exists and no single test is definitive.
This is a major advocacy point. If you are a parent and your son had either of these findings at birth, it is worth asking a pediatric endocrinologist whether a mini-puberty workup was ever done. It rarely is.
• Anosmia or hyposmia. A reduced or absent sense of smell is the hallmark of Kallmann syndrome, a specific genetic form of CHH. Many families have never connected a son’s poor sense of smell to his lack of puberty, but for a pediatric endocrinologist, this is a diagnostic bell-ringer.
• History of cryptorchidism, especially bilateral. Undescended testes at birth suggest the reproductive axis was already failing in fetal life.
• Micropenis. A penis that was notably small at birth points to inadequate androgen exposure in the second and third trimesters.
• Bimanual synkinesia (mirror movements). Involuntary mimicry of one hand’s movements by the other is a neurologic marker associated with certain CHH genotypes.
• Midline defects. Cleft palate, renal malformations, or nystagmus are frequently associated with congenital GnRH deficiency.
• Arrested development. A boy who started puberty but has not progressed in 12+ months, regardless of age, needs evaluation now, not “a little more time.”
None of these findings guarantees CHH, but any of them should trigger a referral to pediatric endocrinology rather than continued observation. The cost of investigating and finding CDGP is a few blood draws; the cost of missing CHH is years of lost bone mass, lost height, and an emotional toll that often persists even after eventual treatment.
The penalty for waiting too long is real. Sex steroids drive both the pubertal growth spurt and the accrual of peak bone mass. Miss that window, and you cannot get it back. Men diagnosed with CHH late in adolescence often have persistently lower bone density as adults, and many ExcelMale members who were treated late describe a sense that their skeleton “never caught up.”
But testosterone has an important limitation. It does not grow the testes, and it does not induce spermatogenesis. For a boy with a temporary issue like CDGP, this does not matter: the testes will develop on their own once his own axis kicks in, and a short course of testosterone simply jump-starts the process. For a boy with CHH, testosterone alone leaves him permanently without meaningful testicular growth, and fertility becomes a complex induction problem in adulthood.
This is where the more “physiological” gonadotropin approach becomes important. The three main options available to pediatric endocrinologists are:
• Testosterone esters (cypionate or enanthate). Low-dose injectable therapy, typically started around 25–50 mg monthly and scaled up over 2–3 years. Fast, simple, standardized. Excellent for CDGP and for the initial virilization phase of CHH when fertility is not an immediate concern.
• Gonadotropins (hCG and FSH). hCG stimulates Leydig cells to produce endogenous testosterone, while FSH drives Sertoli cell proliferation, which determines final testicular volume and future sperm production. A 2024 systematic review of 103 studies and over 5,000 patients found that combined hCG plus FSH therapy induced spermatogenesis in 86% of CHH patients, compared to only 40% with hCG monotherapy. Gonadotropins are complex and more expensive, but for CHH they are often the superior long-term choice.
• Aromatase inhibitors (AIs). In boys where final adult height is a primary concern, AIs can be used to slow epiphyseal plate closure by reducing estrogen-driven bone maturation, theoretically extending the growth window. Evidence remains limited, and AIs are generally reserved for specific cases.
Practically, a common approach for CHH is to start with low-dose testosterone for initial virilization in early adolescence, then transition to combined gonadotropins later to drive testicular growth and spermatogenesis. A 2021 study of 19 CHH patients undergoing gonadotropin-induced puberty found that bilateral cryptorchidism and a strong genetic background predicted a weaker testicular response, while duration of growth during induction depended heavily on the age at which treatment started. The earlier the intervention, the better the outcome.
Secondary Hypo: hCG Monotherapy, Good Test Results, No Relief - A 22-year-old with late puberty and a diagnosis of secondary hypogonadism shares his experience on hCG monotherapy and the frustrations of bloodwork that looks fine while symptoms persist.
Advances in Stem Cell Research for Primary Hypogonadism - A deep dive into Leydig cell biology and emerging therapies for men with primary testicular failure, including those who never completed puberty.
How Men Can Use hCG with Testosterone to Improve Fertility, Libido, and Testicular Size - Comprehensive thread on hCG use including its role in cryptorchidism and in supporting testicular function when TRT has been the only therapy.
Delayed Hypersensitivity Reaction to Testosterone Cypionate Injections - Case report of a 13-year-old with hypergonadotropic hypogonadism on weekly subQ testosterone cypionate for puberty induction, illustrating the practical realities of adolescent TRT protocols.
Best hCG Dose for Men on TRT: Two Studies That Used hCG with Testosterone - Nelson Vergel’s review of hCG dosing research, relevant for anyone managing TRT with a history of incomplete pubertal development.
Testosterone Is a Contraceptive: Should It Not Be Used in Men Who Desire Fertility? - An examination of why testosterone alone shuts down the HPG axis, critical context for anyone weighing testosterone vs. gonadotropin-based puberty induction.
Can hCG Make Your Penis Grow? - Thread discussing hCG dosing research relevant to micropenis and incomplete pubertal virilization, including a reader describing clomiphene and hCG for delayed puberty.
If you are a parent, the action item is straightforward: if your son has not hit the testicular volume of 4 ml by age 14, or if he has any of the red flags described above at any age, do not accept another round of “he will grow when he is ready.” Ask for a referral to pediatric endocrinology and a workup that includes LH, FSH, testosterone, bone age, and consideration of inhibin B and AMH.
If you are an adult man on TRT who was a late bloomer, or who never completed puberty, know that your history matters. The treatment approach that preserves testicular function and fertility looks different from the approach used for age-related low testosterone, and many men in our community have benefited from revisiting their original diagnosis with a fresh set of eyes.
2. Alotaibi MF. A Current Perspective on Delayed Puberty and Its Management. Journal of Clinical Research in Pediatric Endocrinology, 2024;16(4):379–400. Link
3. Howard SR. The Genetic Basis of Delayed Puberty. Frontiers in Endocrinology, 2019;10:423. Link
4. Young J, Xu C, Papadakis GE, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocrine Reviews, 2019;40(2):669–710. Link
5. Rastrelli G, Corona G, Maggi M. Both Comorbidity Burden and Low Testosterone Can Explain Symptoms and Signs of Late-Onset Hypogonadism: A Focus on Pubertal Patterns. Journal of Endocrinological Investigation, 2020;43(6):721–736. Link
6. Rohayem J, Nieschlag E, Zitzmann M, Kliesch S. Testicular Function During Puberty and Young Adulthood in Patients with Klinefelter's Syndrome With and Without Spermatozoa in Seminal Fluid. Andrology, 2016;4(6):1178–1186. Link
7. Nordenström A, Ahmed SF, van den Akker E, et al. Pubertal Induction and Transition to Adult Sex Hormone Replacement in Patients With Congenital Pituitary or Gonadal Reproductive Hormone Deficiency. European Journal of Endocrinology, 2022;186(6):G9–G49. Link
8. Alexander EC, Faruqi D, Farquhar R, et al. Gonadotropins for Pubertal Induction in Males With Hypogonadotropic Hypogonadism: Systematic Review and Meta-analysis. European Journal of Endocrinology, 2024;190(1):S1–S11. Link
9. Cangiano B, Duminuco P, Vezzoli V, et al. Predictors of Reproductive and Non-Reproductive Outcomes of Gonadotropin Mediated Pubertal Induction in Male Patients with Congenital Hypogonadotropic Hypogonadism. Journal of Endocrinological Investigation, 2021;44(12):2729–2742. Link
10. Mason KA, Schoelwer MJ, Rogol AD. Androgens During Infancy, Childhood, and Adolescence: Physiology and Use in Clinical Practice. Endocrine Reviews, 2020;41(3):bnaa003. Link
Key Takeaways • Age 14 is the medical deadline for boys, not a suggestion. If a boy has not reached a testicular volume of 4 ml by age 14, it is time to see a pediatric endocrinologist, not to keep waiting. • Most delayed puberty is benign (Constitutional Delay of Growth and Puberty, or CDGP), but roughly one in three cases is pathological hypogonadism that needs treatment by age 12. • Red flags change everything. Anosmia, cryptorchidism, micropenis, cleft palate, and mirror movements point toward Congenital Hypogonadotropic Hypogonadism and deserve urgent workup. • Testosterone is not the only option. For boys with central hypogonadism, starting with gonadotropins (hCG and FSH) can preserve testicular growth and future fertility that testosterone alone cannot deliver. • Delay costs peak bone mass and adult height. Intervention is a skeletal and psychosocial issue, not a cosmetic one. |
If you are a parent watching your 14-year-old son still look like a 12-year-old, or a man who remembers being the last in your grade to hit a growth spurt, you already know the quiet anxiety that delayed puberty creates. It is tempting to accept the standard reassurance: “He is just a late bloomer. Give it time.” For about two-thirds of boys, that advice is correct. For the other third, it is wrong, and the delay in treatment can cost inches of adult height, lifelong bone density, future fertility, and years of psychosocial well-being.
This guide walks through the distinction that pediatric endocrinologists use to separate Constitutional Delay of Growth and Puberty (CDGP) from Congenital Hypogonadotropic Hypogonadism (CHH) and other pathological causes. You will learn the age-specific decision points, the clinical red flags that should end the “watchful waiting” conversation immediately, and the pharmacological options available once a diagnosis is made. The information here is built on current peer-reviewed literature and two decades of community experience at ExcelMale.com, where many members are living with the downstream consequences of a delayed or missed diagnosis.
What You Will Learn
• The biological definition of delayed puberty and why age 14 is a medical threshold• How clinicians distinguish benign CDGP from permanent hypogonadism
• The red flags that should trigger urgent evaluation rather than reassurance
• When testosterone is the right first-line therapy, and when gonadotropins are better
• The psychosocial and skeletal costs of treating too late
What Is the Medical Definition of Delayed Puberty in Boys?
In clinical practice, male puberty is marked by one specific biological event: testicular enlargement. Pubic hair does not count, because it is driven by adrenal androgens and can appear independently of the reproductive axis. The first true sign of puberty is a testicular volume (TV) of 4 ml measured by a Prader’s orchidometer (or roughly 2.7 ml by ultrasound).About 95% of boys hit this milestone between 9.5 and 13.5 years of age. The “age 14 rule” is a statistical cutoff that sits roughly 2 to 2.5 standard deviations beyond the mean. When a boy reaches age 14 without that 4 ml landmark, he meets the formal definition of delayed puberty, and the question is no longer whether to investigate but what the underlying cause is.
There is a second pattern that is just as important and often missed: arrested puberty. If a boy starts puberty on schedule but then stalls, with no change in genital stage or testosterone for more than a year, or fails to complete development (adult testicular volume of 15 ml and Tanner stage 5) within five years of onset, that is also a medical finding. Starting is only half the battle. The tempo of progression must be tracked too.
How Do Doctors Tell the Difference Between a Late Bloomer and Something More Serious?
This is the most difficult diagnostic problem in adolescent endocrinology. CDGP and CHH can look nearly identical at age 14, because both present with low testosterone and low or normal gonadotropins. The difference is that CDGP is transient, while CHH is a permanent deficiency of GnRH signaling that will not resolve on its own.The three broad categories every clinician considers:
Category | What It Is | Biochemical Fingerprint |
Constitutional Delay (CDGP) | Transient, self-limiting “late bloomer”; ~65% of delayed puberty cases. Usually familial. | Low testosterone, low/normal LH and FSH, bone age delayed by 2+ years. |
Central Hypogonadism (CHH) | Permanent GnRH deficiency. Includes Kallmann syndrome (with anosmia) and normosmic idiopathic forms. | Low testosterone, low/normal LH and FSH - biochemically overlaps with CDGP. |
Primary Hypogonadism | Gonadal failure itself. Klinefelter syndrome (47,XXY), anorchia, radiation or chemotherapy damage. | Low testosterone with high LH and FSH. Karyotype is the next step. |
Primary hypogonadism is easy to identify biochemically because the gonadotropins are elevated. The hard case is separating CDGP from CHH, and the tools available are imperfect. Bone age radiographs help: a significantly delayed bone age relative to chronological age leans toward CDGP. Family history of late puberty in a parent or sibling also favors CDGP. A recent comprehensive review notes that serum inhibin B and anti-Müllerian hormone (AMH) may be valuable differentiators, because they reflect Sertoli cell activity and tend to be lower in CHH than in CDGP. However, overlap exists and no single test is definitive.
Why Is the First Six Months of Life a Missed Diagnostic Window?
During the first six months of life, the hypothalamic-pituitary-gonadal axis undergoes a “mini-puberty”, a brief test run where gonadotropin and testosterone levels approach pubertal ranges before the axis goes quiet for the rest of childhood. This window is a powerful diagnostic opportunity. An infant boy presenting with cryptorchidism (undescended testes), micropenis, or bilateral testicular issues can be evaluated during mini-puberty using LH, testosterone, inhibin B, and AMH. A flat response strongly suggests CHH and can be identified before the child even starts school, rather than waiting until age 14 for a diagnosis.This is a major advocacy point. If you are a parent and your son had either of these findings at birth, it is worth asking a pediatric endocrinologist whether a mini-puberty workup was ever done. It rarely is.
What Red Flags Should End the “Watchful Waiting” Conversation Immediately?
Several clinical findings dramatically shift the odds away from benign CDGP and toward permanent pathology. If any of these are present, extended observation is no longer appropriate.• Anosmia or hyposmia. A reduced or absent sense of smell is the hallmark of Kallmann syndrome, a specific genetic form of CHH. Many families have never connected a son’s poor sense of smell to his lack of puberty, but for a pediatric endocrinologist, this is a diagnostic bell-ringer.
• History of cryptorchidism, especially bilateral. Undescended testes at birth suggest the reproductive axis was already failing in fetal life.
• Micropenis. A penis that was notably small at birth points to inadequate androgen exposure in the second and third trimesters.
• Bimanual synkinesia (mirror movements). Involuntary mimicry of one hand’s movements by the other is a neurologic marker associated with certain CHH genotypes.
• Midline defects. Cleft palate, renal malformations, or nystagmus are frequently associated with congenital GnRH deficiency.
• Arrested development. A boy who started puberty but has not progressed in 12+ months, regardless of age, needs evaluation now, not “a little more time.”
None of these findings guarantees CHH, but any of them should trigger a referral to pediatric endocrinology rather than continued observation. The cost of investigating and finding CDGP is a few blood draws; the cost of missing CHH is years of lost bone mass, lost height, and an emotional toll that often persists even after eventual treatment.
When Should Hormone Treatment Actually Start?
The timing rules are specific and differ based on the diagnosis:Clinical Situation | Recommended Timing | Rationale |
Suspected CDGP, no red flags, no severe psychosocial distress | Watchful waiting between ages 12–14 is reasonable | Most boys will begin puberty spontaneously; intervention is not always needed. |
Confirmed CDGP at age 14 with no spontaneous progression | Treatment should not be delayed beyond age 14 | Preserves growth spurt and peak bone mass accrual. |
Confirmed primary or central hypogonadism | Proposed by chronological age 11.5–12 and bone age >11 | Align pubertal timing with peers; protect bone and psychosocial development. |
Arrested puberty (no progression >1 year) | Start therapy regardless of age | Stalling is itself a sign of likely pathological hypogonadism. |
The penalty for waiting too long is real. Sex steroids drive both the pubertal growth spurt and the accrual of peak bone mass. Miss that window, and you cannot get it back. Men diagnosed with CHH late in adolescence often have persistently lower bone density as adults, and many ExcelMale members who were treated late describe a sense that their skeleton “never caught up.”
Is Testosterone the Only Treatment, or Are There Better Options for Some Boys?
Testosterone is the traditional first-line therapy for pubertal induction because it is standardized, inexpensive, and reliably produces the visible signs of virilization: voice deepening, facial and body hair, muscle mass, and a growth spurt. It works because testosterone is aromatized into estradiol, which upregulates growth hormone secretion and drives linear growth. (This is why DHT, a non-aromatizable androgen, cannot produce a growth spurt on its own.)But testosterone has an important limitation. It does not grow the testes, and it does not induce spermatogenesis. For a boy with a temporary issue like CDGP, this does not matter: the testes will develop on their own once his own axis kicks in, and a short course of testosterone simply jump-starts the process. For a boy with CHH, testosterone alone leaves him permanently without meaningful testicular growth, and fertility becomes a complex induction problem in adulthood.
This is where the more “physiological” gonadotropin approach becomes important. The three main options available to pediatric endocrinologists are:
• Testosterone esters (cypionate or enanthate). Low-dose injectable therapy, typically started around 25–50 mg monthly and scaled up over 2–3 years. Fast, simple, standardized. Excellent for CDGP and for the initial virilization phase of CHH when fertility is not an immediate concern.
• Gonadotropins (hCG and FSH). hCG stimulates Leydig cells to produce endogenous testosterone, while FSH drives Sertoli cell proliferation, which determines final testicular volume and future sperm production. A 2024 systematic review of 103 studies and over 5,000 patients found that combined hCG plus FSH therapy induced spermatogenesis in 86% of CHH patients, compared to only 40% with hCG monotherapy. Gonadotropins are complex and more expensive, but for CHH they are often the superior long-term choice.
• Aromatase inhibitors (AIs). In boys where final adult height is a primary concern, AIs can be used to slow epiphyseal plate closure by reducing estrogen-driven bone maturation, theoretically extending the growth window. Evidence remains limited, and AIs are generally reserved for specific cases.
Practically, a common approach for CHH is to start with low-dose testosterone for initial virilization in early adolescence, then transition to combined gonadotropins later to drive testicular growth and spermatogenesis. A 2021 study of 19 CHH patients undergoing gonadotropin-induced puberty found that bilateral cryptorchidism and a strong genetic background predicted a weaker testicular response, while duration of growth during induction depended heavily on the age at which treatment started. The earlier the intervention, the better the outcome.
Frequently Asked Questions About Delayed Puberty in Boys
Is delayed puberty hereditary?
CDGP is strongly familial. If the father was a late bloomer, the son is much more likely to follow the same pattern. Genetic causes of CHH, including Kallmann syndrome, also have inheritance patterns, and a family history of infertility, anosmia, or delayed puberty in multiple relatives should prompt genetic counseling.Will my son eventually reach a normal adult height if he is a late bloomer?
In most cases of true CDGP, yes. Boys with CDGP generally reach a height within their target family range, though often later than their peers. The concern is when the delay is pathological rather than constitutional. This is why treatment decisions at age 14 are not cosmetic; they protect growth potential.Does short-term testosterone therapy in adolescence cause long-term dependence?
For true CDGP, a short 3–6 month course of low-dose testosterone does not disrupt the subsequent natural onset of puberty; the evidence consistently shows that boys who get a “jump-start” still enter spontaneous puberty on their own axis afterward. For boys with confirmed hypogonadism, long-term replacement is typically lifelong, because the underlying defect does not resolve.Why do some men who were late bloomers still feel the effects decades later?
Quality-of-life studies consistently show that men who experienced significant delayed puberty report lower scores in emotional well-being and social function, even years after their bodies caught up. The experience of feeling “left behind” during a formative social period can leave marks that pharmacological therapy alone does not erase. Psychological support alongside hormonal treatment is often warranted.Does a history of delayed puberty increase the risk of adult hypogonadism?
Yes, particularly when the delay was due to undiagnosed or partially-treated CHH. Some adult men on TRT in the ExcelMale community have, on careful history-taking, a clinical picture that traces back to incomplete pubertal development in adolescence. If you are an adult man with low testosterone and you were a late bloomer who “never quite caught up,” it is worth asking whether partial CHH was missed.Related ExcelMale Forum Discussions
Testopel vs Injections and hCG: Very Confused - A 22+ year member with idiopathic hypogonadotropic hypogonadism discusses what happens when a man is diagnosed after never going through puberty and is put on testosterone alone, without hCG.Secondary Hypo: hCG Monotherapy, Good Test Results, No Relief - A 22-year-old with late puberty and a diagnosis of secondary hypogonadism shares his experience on hCG monotherapy and the frustrations of bloodwork that looks fine while symptoms persist.
Advances in Stem Cell Research for Primary Hypogonadism - A deep dive into Leydig cell biology and emerging therapies for men with primary testicular failure, including those who never completed puberty.
How Men Can Use hCG with Testosterone to Improve Fertility, Libido, and Testicular Size - Comprehensive thread on hCG use including its role in cryptorchidism and in supporting testicular function when TRT has been the only therapy.
Delayed Hypersensitivity Reaction to Testosterone Cypionate Injections - Case report of a 13-year-old with hypergonadotropic hypogonadism on weekly subQ testosterone cypionate for puberty induction, illustrating the practical realities of adolescent TRT protocols.
Best hCG Dose for Men on TRT: Two Studies That Used hCG with Testosterone - Nelson Vergel’s review of hCG dosing research, relevant for anyone managing TRT with a history of incomplete pubertal development.
Testosterone Is a Contraceptive: Should It Not Be Used in Men Who Desire Fertility? - An examination of why testosterone alone shuts down the HPG axis, critical context for anyone weighing testosterone vs. gonadotropin-based puberty induction.
Can hCG Make Your Penis Grow? - Thread discussing hCG dosing research relevant to micropenis and incomplete pubertal virilization, including a reader describing clomiphene and hCG for delayed puberty.
The Bottom Line: Why Acting on Time Matters More Than the Diagnosis Itself
Delayed puberty is one of the few areas of adolescent medicine where “wait and see” has a hard deadline. Age 14 for suspected CDGP, age 12 for confirmed hypogonadism, and any time for arrested puberty. Miss those deadlines and the consequences compound: shorter adult stature, lower peak bone mass, reduced testicular development, harder fertility induction later, and a psychosocial burden that often outlasts the physical catch-up.If you are a parent, the action item is straightforward: if your son has not hit the testicular volume of 4 ml by age 14, or if he has any of the red flags described above at any age, do not accept another round of “he will grow when he is ready.” Ask for a referral to pediatric endocrinology and a workup that includes LH, FSH, testosterone, bone age, and consideration of inhibin B and AMH.
If you are an adult man on TRT who was a late bloomer, or who never completed puberty, know that your history matters. The treatment approach that preserves testicular function and fertility looks different from the approach used for age-related low testosterone, and many men in our community have benefited from revisiting their original diagnosis with a fresh set of eyes.
Key References
1. Bizzarri C, Cappa M. Ontogeny of Hypothalamus-Pituitary-Gonadal Axis and Minipuberty: An Ongoing Debate? Frontiers in Endocrinology, 2020. Link2. Alotaibi MF. A Current Perspective on Delayed Puberty and Its Management. Journal of Clinical Research in Pediatric Endocrinology, 2024;16(4):379–400. Link
3. Howard SR. The Genetic Basis of Delayed Puberty. Frontiers in Endocrinology, 2019;10:423. Link
4. Young J, Xu C, Papadakis GE, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocrine Reviews, 2019;40(2):669–710. Link
5. Rastrelli G, Corona G, Maggi M. Both Comorbidity Burden and Low Testosterone Can Explain Symptoms and Signs of Late-Onset Hypogonadism: A Focus on Pubertal Patterns. Journal of Endocrinological Investigation, 2020;43(6):721–736. Link
6. Rohayem J, Nieschlag E, Zitzmann M, Kliesch S. Testicular Function During Puberty and Young Adulthood in Patients with Klinefelter's Syndrome With and Without Spermatozoa in Seminal Fluid. Andrology, 2016;4(6):1178–1186. Link
7. Nordenström A, Ahmed SF, van den Akker E, et al. Pubertal Induction and Transition to Adult Sex Hormone Replacement in Patients With Congenital Pituitary or Gonadal Reproductive Hormone Deficiency. European Journal of Endocrinology, 2022;186(6):G9–G49. Link
8. Alexander EC, Faruqi D, Farquhar R, et al. Gonadotropins for Pubertal Induction in Males With Hypogonadotropic Hypogonadism: Systematic Review and Meta-analysis. European Journal of Endocrinology, 2024;190(1):S1–S11. Link
9. Cangiano B, Duminuco P, Vezzoli V, et al. Predictors of Reproductive and Non-Reproductive Outcomes of Gonadotropin Mediated Pubertal Induction in Male Patients with Congenital Hypogonadotropic Hypogonadism. Journal of Endocrinological Investigation, 2021;44(12):2729–2742. Link
10. Mason KA, Schoelwer MJ, Rogol AD. Androgens During Infancy, Childhood, and Adolescence: Physiology and Use in Clinical Practice. Endocrine Reviews, 2020;41(3):bnaa003. Link
